Michael Roehrle

HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection

M. Buti, G. Kukolj, C. Sarrazin, 2016, Clinical and experimental gastroenterology.

Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers

A. Schmitt-Hoffmann, B. Roos, E. Weidekamm, 2006, Antimicrobial Agents and Chemotherapy.

Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers

C. Beglinger, A. Schmitt-Hoffmann, B. Roos, 2006, Antimicrobial Agents and Chemotherapy.

Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease

B. Dubois, L. Frölich, Glen R. Wunderlich, 2018, Alzheimer's Research & Therapy.

Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease

B. Dubois, L. Frölich, C. Thamer, 2019, Alzheimer's Research & Therapy.

Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease

B. Dubois, L. Frölich, C. Thamer, 2019, Alzheimer's Research & Therapy.